AGLIETTA, MASSIMO
 Distribuzione geografica
Continente #
NA - Nord America 323
EU - Europa 187
AS - Asia 102
SA - Sud America 9
AF - Africa 2
Totale 623
Nazione #
US - Stati Uniti d'America 316
GB - Regno Unito 54
SG - Singapore 53
DE - Germania 52
SE - Svezia 22
RU - Federazione Russa 17
CN - Cina 16
HK - Hong Kong 15
IT - Italia 15
BR - Brasile 7
IN - India 7
UA - Ucraina 6
CA - Canada 4
FI - Finlandia 4
FR - Francia 4
TR - Turchia 4
BE - Belgio 3
VN - Vietnam 3
AT - Austria 2
BG - Bulgaria 2
JP - Giappone 2
LT - Lituania 2
AL - Albania 1
AR - Argentina 1
CL - Cile 1
CR - Costa Rica 1
DM - Dominica 1
EG - Egitto 1
ES - Italia 1
ID - Indonesia 1
MA - Marocco 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PL - Polonia 1
Totale 623
Città #
Singapore 45
Ashburn 39
Southend 38
Fairfield 33
Houston 33
Santa Clara 24
Woodbridge 24
Cambridge 19
Chandler 17
Wilmington 15
Ann Arbor 14
Hong Kong 14
Los Angeles 12
Nyköping 12
Seattle 12
Dearborn 7
London 7
Jacksonville 5
Modena 5
Beijing 4
Chicago 4
Eugene 4
Izmir 4
Moscow 4
Brussels 3
Helsinki 3
San Diego 3
The Dalles 3
Toronto 3
Bremen 2
Florence 2
Guntur 2
Hyderabad 2
Milan 2
Munich 2
Nanjing 2
New York 2
Parma 2
Princeton 2
Salt Lake City 2
Sofia 2
Tokyo 2
Albuquerque 1
As 1
Balcarce 1
Bangalore 1
Bismarck 1
Biên Hòa 1
Boardman 1
Boguchany 1
Casablanca 1
Central 1
Chennai 1
Da Nang 1
Dedham 1
Denver 1
Giza 1
Greenville 1
Guarulhos 1
Ho Chi Minh City 1
Kuala Lumpur 1
Kyiv 1
Lages 1
Machado 1
Montreal 1
Mumbai 1
Nanning 1
Orem 1
Panama City 1
Philadelphia 1
Phoenix 1
Pindamonhangaba 1
Pittsburgh 1
Ponta Porã 1
Poplar 1
Prescot 1
Redondo Beach 1
Roseau 1
San Jose 1
San José 1
Shanghai 1
Stanford 1
São Paulo 1
Talca 1
Tirana 1
Turku 1
Vienna 1
Warsaw 1
Totale 482
Nome #
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 366
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 263
Totale 629
Categoria #
all - tutte 2.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.121


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202142 0 0 0 0 0 1 13 7 3 8 5 5
2021/202251 1 12 1 5 1 4 3 5 4 1 9 5
2022/202361 9 9 5 4 11 3 4 5 4 2 3 2
2023/202433 0 2 1 3 8 1 7 4 0 1 3 3
2024/202596 8 0 3 8 16 11 6 6 17 3 6 12
2025/202692 11 4 6 18 37 16 0 0 0 0 0 0
Totale 629